Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advisory Panel For Bristol's Yervoy Is Called Off, Which May Bode Well

This article was originally published in The Pink Sheet Daily

Executive Summary

After extending the review, FDA says it no longer needs ODAC's advice on the second-line melanoma treatment, which looks like a good sign for approval.

You may also be interested in...



Yervoy Cuts To The Head Of The Line: Ipilimumab Has Unrestricted Label

Bristol-Myers Squibb's immunotherapy Yervoy (ipilimumab) will enter the market positioned for wide use, with a broad label for its approval for metastatic melanoma and positive Phase III results for front-line patients.

Yervoy Cuts To The Head Of The Line: Ipilimumab Has Unrestricted Label

Bristol-Myers Squibb's immunotherapy Yervoy (ipilimumab) will enter the market positioned for wide use, with a broad label for its approval for metastatic melanoma and positive Phase III results for front-line patients.

Plexxikon, Roche Near Catalyst For BRAF Inhibitor In Melanoma

As its melanoma drug advances in the clinic, Plexxikon obtains rights to co-promote it in the U.S.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel